Biomarkers of Muscle Anabolism (MK-0000-082)

Phase 1

Completed

• Conditions: Muscle Anabolism

• Registration Number: NCT00812396
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

This study will evaluate the ability of comparative proteomics to identify early biomarkers of muscle anabolism.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-11
• Primary Completion: 2008-02
• Study Completion: 2008-02
• Study First Submitted: 2008-12-19
• Study First Submitted QC: 2008-12-19
• Study First Posted: 2008-12-22
• Status Verified: 2015-01
• Last Update Submitted: 2015-01-29
• Last Update Posted: 2015-01-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 30

Inclusion Criteria

• subject is a healthy male between 18 and 40 years old
• subject's weight is stable over the past 3 months
• subject agrees to refrain from consuming alcohol during study
• subject agrees to consume no caffeine while in the CRU
• subject agrees to follow meat-free diet
• subject is willing to avoid strenuous activity
• subject has been a nonsmoker for at least 6 months

Exclusion Criteria

• subject is a regular user of illicit drugs
• subject has taken androgenic steroids in the past 12 months
• subject has participated in sports events, resistance training, or moderate to heavy endurance training in the past month
• subject has prostate cancer
• subject has HIV and/or hepatitis B or C

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
comparative proteomics on proteins present in the vastus lateralis or plasma	1 week

Secondary Outcome Measures

Name	Time	Method
mRNA or miRNA expression in the vastus lateralis or in peripheral blood	1 week